CTRIP: MMPI-PARI-BASED INTERVENTIONS IN ARTERIAL THROMBOSIS

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 该项目正在评估PAR 1-MMP抑制剂联合分子在急性血栓性疾病中的治疗潜力。特别是，这项工作是生物药物开发项目的一部分，这些新的化合物，旨在用于急性冠状动脉综合征和血管成形术/支架适应症。这项工作将确定静脉内给药递增剂量的PZ-128在狒狒动脉血栓形成模型中的抗血栓形成疗效、止血安全性、药效学（PD）和药代动力学（PK）。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. This project is evaluating the therapeutic potential of a combined PAR1-MMP inhibitor molecule in acute thrombotic diseases. In particular, this work is part of biological drug development project for these novel compounds that are intended for use in acute coronary syndrome and angioplasty/stenting indications. The work will determine antithrombotic efficacy, hemostatic safety, pharmacodynamics (PD) and pharmacokinetics (PK) of intravenously administered escalating doses of PZ-128 in baboon models of arterial thrombosis.